THAKKAR ANJALI artificial blood

Information about THAKKAR ANJALI artificial blood

Published on October 16, 2007

Author: funnyside

Source: authorstream.com

Content

Artificial Blood The blood of the future :  Artificial Blood The blood of the future By Anjali Thakkar COSMOS 2007 Cluster 1 Mentor: Professor Paul Feldstein The History of Artificial Blood:  The History of Artificial Blood Milk was one of the first substances used as a blood substitute in order to treat patients with Asiatic cholera. (Squires 1). After several patients died by receiving milk transfusions, other substances were discovered as potentials (Squires 1): Salt or saline solutions: used primarily as a plasma volume expander, rather than as artificial blood Hemoglobin isolated from red blood cells Animal plasma could be used as a substitute for human blood However, since many of the materials in animal plasma are toxic to humans, this posed a problem to using it as a substitute The problem of not having a workable substitute led to Ringer’s Solution… Ringer’s Solution:  Ringer’s Solution Created by the physiologist Sydney Ringer in 1882 Ringer’s solution is a saline solution which is able to prolong the life of cells in the body Solution contains sodium chloride, potassium chloride, calcium chloride, and sodium bicarbonate: designed in the concentrations found in the human body to keep the heart pumping even outside of the body This solution resembles blood serum Often used to culture animal cells (Encyclopedia Britannica) Blood Grouping: Karl Landsteiner:  Blood Grouping: Karl Landsteiner http://nobelprize.org/nobel_prizes/medicine/laureates/1930/landsteiner.jpg Karl Landsteiner was a world-renowned immunologist and pathologist in the 1900s. contributed to the world of medicine in the fields of anatomy, histology, and immunology 1909: Landsteiner classified human blood into four different groups: A, B, AB, and O Recognized the agglutinins in the blood This has become the basis for modern blood typing today received the Nobel Prize for Physiology or Medicine in 1930 (Nobel Foundation) Artificial Blood vs. Blood Substitutes:  Artificial Blood vs. Blood Substitutes Ideal Characteristics of Artificial Blood:  Ideal Characteristics of Artificial Blood Safe to use Compatible in the human body Able to transport and release oxygen where needed Storable and durable for longer time periods Is free of pathogens and toxins which would produce an immune system response in the human body (Squires 3). Problems Currently Associated with Artificial Blood and Blood Substitutes:  Problems Currently Associated with Artificial Blood and Blood Substitutes Bodily immune systems may sometimes react negatively to the foreign blood that is inserted into the body (Goorha et al 46). Trauma/Shock Patients Since these patients are often frequent recipients of blood substitutes or plasma during surgery, it becomes challenging to understand which types of blood substitutes have affected which problem in the patient’s body (Winslow 2). Currently no real working source of artificial blood exists that can perform the multifarious tasks of real human blood cells (Goorha et al 46). Types of Blood Substitutes Perfluorocarbons (PFC) emulsions:  Types of Blood Substitutes Perfluorocarbons (PFC) emulsions Perfluorocarbons are derived from a group of hydrocarbons in which the hydrogen atoms are replaced by fluorine atoms. PFCs are chemically inert due to the strength of the carbon-fluorine bonds Used to create artificial blood during surgeries Process of production: Water, salts, and phospholipids surfactant are added and emulsified through high-pressure homogenization Purified through high temperatures of steam (Goorha et al 47-48). Common PFCs: Perfluorodecalin Perflubron Types of Blood Substitutes Perfluorocarbons (PFC) emulsions:  Types of Blood Substitutes Perfluorocarbons (PFC) emulsions Oxygenation: Saturation occurs with PFCs passively as oxygen molecules “dissolve into molecular cavities within droplets of the liquid” ("Types of Blood Substitutes”) Thus, the oxygenation of PFCs is directly related to the partial pressure of oxygen which is in contact with the PFC (See figure below) "Types of Blood Substitutes." eurobloodsubstitutes.com. 2007. Euro Blood Substitutes. 31 Jul 2007 <http://www.eurobloodsubstitutes.com/pfcInfo.htm>. Types of Blood Substitutes Perfluorocarbons (PFC) emulsions:  Types of Blood Substitutes Perfluorocarbons (PFC) emulsions Structure: Perfluorocarbon core Surrounded by a phospholipid surfactant (Werlin et al) A surfactant is “a substance that reduces the surface tension of the liquid in which it is dissolved” (Brown, useful definitions) http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/10/webpages/PFClink.htm Types of Blood Substitutes Perfluorocarbons (PFC) emulsions:  Types of Blood Substitutes Perfluorocarbons (PFC) emulsions Types of Blood Substitutes Hemoglobin-based Oxygen Carriers (HBOCs):  Types of Blood Substitutes Hemoglobin-based Oxygen Carriers (HBOCs) Hemoglobin-based Oxygen Carriers were created as a mechanism to mimic the oxygen-carrying role of hemoglobin in the body, while still reducing the need for real human hemoglobin. Hemoglobin is a tetramer with two alpha and two beta polypeptide chains; each is bound to an iron heme group which successively binds to an oxygen molecule Hemoglobin’s heme bond allows it to have a higher affinity for oxygen, thus making it an excellent source of blood substitutes. (Goorha et al 46). Types of Blood Substitutes Hemoglobin-based Oxygen Carriers (HBOCs):  Types of Blood Substitutes Hemoglobin-based Oxygen Carriers (HBOCs) Currently, experimentation is occurring to develop vesicles which carry the Hemoglobin before inserting it into the body as an HBOC There are several advantages to HBOC carrier vesicles Prevents the denaturation of the Hemoglobin The vesicles themselves are made of purified Hb and lipids, making them compatible with the human immune system Current Setbacks with Hb Vesicle Technology Materials such as nylon, gelatin, and gum arabic have been tried but the human immune system, specifically the reticuloendothelial system, removed the vesicle promptly as a natural bodily response. Later, the theory of phospholipid vessels was used to create a vesicle using phospholipids Researchers are trying to develop a way to create liposome sacks to carry the HBOCs (Goorha et al) Types of Blood Substitutes:  Types of Blood Substitutes Goorha, Brig, and Maj Deb. "Artificial Blood." MJAFI 59(2003): 45-49. Types of Blood Substitutes:  Types of Blood Substitutes Goorha, Brig, and Maj Deb. "Artificial Blood." MJAFI 59(2003): 45-49. This figure displays the different forms of blood substitutes that can be used to simulate the actions of a red blood cell Researchable Question:  Researchable Question Can we make a blood substitute using Biotechnological techniques? In order to create a blood substitute that would effectively transport oxygen throughout the body, the hemoglobin gene would have to be inserted in a plasmid vector and multiplied in a specific medium. The hemoglobin gene would be inserted into the plasmid to carry the cloned gene into E. Coli cells This would allow for expression of large amounts of the hemoglobin protein Escherichia Coli P678-54:  Escherichia Coli P678-54 The particular strain of the bacteria E. Coli P678-54 has the unique property of dividing abnormally – it forms a mother cell and a daughter cell (Marszalone et al 1219) The mother cell is similar to a regular cell in that it contains chromosomal DNA. However, it contains ALL of the cell’s DNA The daughter cell is achromosomal. It is smaller, and contains no chromosomal DNA. The daughter cell is often referred to as a “mini cell” Because E. Coli P678-54 has the property of dividing abnormally, it would be ideal if used as a Gene Delivery Vehicle, or GDV (Cohen et al 64). Since E. Coli P678-54 has a tendency to divide into mother cells as well as mini cells, these mini cells could be ideal for the creation of hemoglobin-based oxygen carriers (Giacalone et al 1). Method of HBOC production using E. Coli P678-54 Mini cells:  Method of HBOC production using E. Coli P678-54 Mini cells In order to produce a hemoglobin-based oxygen carrier using E. Coli P678-54 mini cells, the hemoglobin gene must be inserted into the E. Coli bacterium. The general process to insert hemoglobin into E. Coli cells uses several techniques of biotechnology: PCR – to assemble the human hemoglobin gene Western Blotting – to ensure that the substance being produced really is the Hemoglobin protein Inoculation – to grow the E. Coli cells after transformation Electroporation – to open the E. Coli cell pores and allow the plasmid vectors containing the Hb gene to enter Blue/White Screening – to test whether or not the E. Coli cells have been successfully transformed with the Hb gene Gene Transformation – to incorporate the Hb gene into E. Coli DNA through plasmid vectors Enzyme digestion – to properly insert the Hb gene into the plasmid vector containing the lacZ indicator gene Experimental Design - Materials:  Experimental Design - Materials Agar gel plate with Ampicillin antibiotic Plasmids with the lacZ indicator gene Micropipettes E. Coli P678-54 cells Human DNA Primers (to make complete PCR products of the human hemoglobin gene) Experimental Design – Methods Hemoglobin Gene Preparation:  Experimental Design – Methods Hemoglobin Gene Preparation Preparation of Hemoglobin Obtain and purify hemoglobin DNA Use primers to cut hemoglobin DNA and remove introns Use modification methods to ensure that the cell free hemoglobin does not break down and lose its properties This newly assembled hemoglobin DNA can be used as a PCR product PCR Product: PCR buffer dNTP Hemoglobin primer mix Sterile water PCR (Polymerase Chain Reaction) Run the PCR product through a PCR machine Inserting hemoglobin into plasmid vectors Using a plasmid vector with the lacZ indicator gene, we can insert the hemoglobin DNA along with primers for both ends so that the hemoglobin can enter the plasmid This plasmid now contains the recombinant hemoglobin DNA Experimental Design – Methods Transformation of E. Coli Cells:  Experimental Design – Methods Transformation of E. Coli Cells The plasmid vectors are inserted into E. Coli P678-54 Insert the plasmid vectors into a solution containing E. Coli P678-54 Place the solution through “electroporation”: This allows the plasmid vectors to enter the E. Coli cells by opening up pores in the E. Coli Blue/White Screening Once the plasmid vectors have been inserted into the E. Coli cells, spread the transformed cells onto an agar plate with the Ampicillin antibiotic White colonies: represent colonies which have hemoglobin properly inserted into the plasmids  the hemoglobin plasmid has successfully broken the lacZ gene region Blue colonies: represent colonies which haven’t been properly transformed: the lacZ gene displays the blue color; thus, colonies that show the blue color have the lacZ region still intact, meaning that the hemoglobin gene has not been incorporated into the region Experimental Design – Methods Mini Cell Separation:  Experimental Design – Methods Mini Cell Separation Separation of Mini Cells from normal cells Suspend the solution by microcentrifuging it Mini cells will be suspended higher than the normal cells as they are less dense Pipette out the supernatant above the mini cells Pipette the mini cells without disturbing the normal E. Coli cells Experimental Design – Methods Testing for Oxygen:  Experimental Design – Methods Testing for Oxygen Testing transformed E. Coli minicells for oxygen content a simple way to test the transformed mini cells for oxygen binding to hemoglobin would be to check whether the cells are red or blue Oxygenated blood = red Deoxygenated blood = blue Check the Hemoglobin Saturation percentage (Wikipedia) This is a sigmoidal (non-linear) function which measures the partial pressure of oxygen In a healthy human being, 98.5% of the oxygen is bound to Hemoglobin, thus making it oxygenated 1.5% of the oxygen is bound to other liquids, making it inaccessible How to check Infrared absorption between oxygenated and deoxygenated blood varies highly, thus allowing hospitals and other clinics to differentiate between oxygenated blood and deoxygenated blood Experimental Design – Methods Hemoglobin Modification Methods:  Experimental Design – Methods Hemoglobin Modification Methods Ensuring the stability of hemoglobin When hemoglobin is left outside a cell, it has the tendency to break into its individual parts, instead of remaining as an entire hemoglobin protein (“Types of Blood Substitutes”) Methods have been discovered to retain the stability of hemoglobin including: "Types of Blood Substitutes." eurobloodsubstitutes.com. 2007. Euro Blood Substitutes. 31 Jul 2007 Further Research:  Further Research Since hemoglobin has been inserted into E. Coli cells, the body’s immune system will most likely develop antibodies to combat the foreign E. Coli cells that are inserted Option 1: the mini cells could be packaged in a liposome to trick the immune system (Li 3761). Option 2: we could find the gene in E. Coli that stimulates the production of antibodies and use gene silencing techniques to turn the gene off Works Cited:  Works Cited Cohen, Amikam and W. D. Fisher. "DNA Isolated from Escherichia Coli Minicells Mated with F+ Cells." Proceedings of the National Academy of Sciences of the United States of America 61 (1968) 61-68. 17/07/2007. Giacalone , Matthew, and Gentile, Angela, and Lovitt, Brian, and Xu, Tong, and Sabbadini, Roger, and Surbur, Mark. "The Use of Bacterial Minicells to transfer Plasmid DNA to eukaryotic cells." Cellular Microbiology 8 (2006) 1624-1633. 16/07/2007 <www.blackwell-synergy.com/doi/pdf/10.1111/j.1462-5822.2006.00737.x>. Goorha, Brig, and Maj Deb. "Artificial Blood." MJAFI 59(2003): 45-49. Li, Shuliang. "Liposome-encapsulated actin–hemoglobin (LEAcHb) artificial blood substitutes." Biomaterials 26June 2005 3759-3769. <http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TWB-4DN13MC-1&_user=4421&_coverDate=06%2F01%2F2005&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000059598&_version=1&_urlVersion=0&_userid=4421&md5=795149aeb4f49af0ef50ad656ed4c02a>. Works Cited:  Works Cited Marszalek, Piotr and Tian Tsong. "Cell Fission and Formation of Mini Cell Bodies by High Frequency Alternating Electric Field." Biophysical Journal 68 April 1995 1218-1221. 17/07/2007. Nobel Foundation, "Karl Landsteiner." Nobelprize.org. 2007. Nobel Foundation. 31 Jul 2007 <http://nobelprize.org/nobel_prizes/medicine/laureates/1930/landsteiner-bio.html>. “Ringer's solution." Encyclopedia Britannica. 2007. Encyclopedia Britannica Online. 23 July 2007  <http://www.britannica.com/eb/article-9063724>. Squires, Jerry E. "Artificial Blood." Science 295February 2002 1002-1005. 17/07/2007 <http://www.sciencemag.org/cgi/content/full/295/5557/1002>. "Types of Blood Substitutes." eurobloodsubstitutes.com. 2007. Euro Blood Substitutes. 31 Jul 2007 <http://www.eurobloodsubstitutes.com/pfcInfo.htm>. Werlin, Evan. "Current Synthetic Blood Products." biomed.brown.edu. April 2005. Brown University. 31 Jul 2007 http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/10/webpages/PFClink.htm Wikipedia, "Blood." Wikipedia.com. July 2007. Wikipedia. 31 Jul 2007 <http://en.wikipedia.org/wiki/Blood>.

Related presentations


Other presentations created by funnyside

HCM Luzern
18. 06. 2007
0 views

HCM Luzern

lecture12
12. 10. 2007
0 views

lecture12

basketball
01. 08. 2007
0 views

basketball

Atacama Large Millimeter Array
15. 06. 2007
0 views

Atacama Large Millimeter Array

gen mtgmar07 slides
18. 06. 2007
0 views

gen mtgmar07 slides

20030815 RepICFA HN
27. 09. 2007
0 views

20030815 RepICFA HN

Owen
03. 10. 2007
0 views

Owen

14BBlackHoles
07. 10. 2007
0 views

14BBlackHoles

Noda06
09. 10. 2007
0 views

Noda06

reptile
10. 10. 2007
0 views

reptile

leskov
15. 10. 2007
0 views

leskov

461
17. 10. 2007
0 views

461

Europe Presentation
19. 10. 2007
0 views

Europe Presentation

RadOnc
22. 10. 2007
0 views

RadOnc

schnittsysteme
23. 10. 2007
0 views

schnittsysteme

ch1 10 part2
23. 10. 2007
0 views

ch1 10 part2

firma end Presentation
19. 10. 2007
0 views

firma end Presentation

sta291 5c
29. 10. 2007
0 views

sta291 5c

ACM India Studies 2005
26. 11. 2007
0 views

ACM India Studies 2005

Mirabel
01. 12. 2007
0 views

Mirabel

ghana
10. 12. 2007
0 views

ghana

DanishCitationEventJB final
15. 10. 2007
0 views

DanishCitationEventJB final

aleynikov
26. 10. 2007
0 views

aleynikov

ShortageChicago Seago 2
29. 10. 2007
0 views

ShortageChicago Seago 2

Daylight Saving Time
07. 11. 2007
0 views

Daylight Saving Time

unity
21. 08. 2007
0 views

unity

Fad Diets
21. 08. 2007
0 views

Fad Diets

NACADA Combined Workshop
21. 08. 2007
0 views

NACADA Combined Workshop

TeraGrid SC06 1
22. 10. 2007
0 views

TeraGrid SC06 1

plane parallel 2 1
24. 10. 2007
0 views

plane parallel 2 1

cronologia storia contemporanea
13. 11. 2007
0 views

cronologia storia contemporanea

IDitarod
16. 11. 2007
0 views

IDitarod

Axiome Von Neumann Morgenstern
19. 11. 2007
0 views

Axiome Von Neumann Morgenstern

Dog bite sepsis
19. 11. 2007
0 views

Dog bite sepsis

Girish
21. 11. 2007
0 views

Girish

EcoValidity
17. 12. 2007
0 views

EcoValidity

matthew
29. 12. 2007
0 views

matthew

Cyatheaceae Classification
02. 01. 2008
0 views

Cyatheaceae Classification

RFF Shinnecock
03. 01. 2008
0 views

RFF Shinnecock

AustralianPoetry
03. 01. 2008
0 views

AustralianPoetry

dbl dutch
22. 11. 2007
0 views

dbl dutch

Lecture10 overheads
21. 08. 2007
0 views

Lecture10 overheads

Deborah Russell Presentation
14. 11. 2007
0 views

Deborah Russell Presentation

AAPT v3
01. 08. 2007
0 views

AAPT v3

EScannapieco
15. 11. 2007
0 views

EScannapieco

Successful  Case  Studies
29. 09. 2007
0 views

Successful Case Studies

Interv Hajji
23. 10. 2007
0 views

Interv Hajji

khelif edson rep
09. 10. 2007
0 views

khelif edson rep

aadcrocodile
11. 10. 2007
0 views

aadcrocodile

matricole
16. 10. 2007
0 views

matricole

the three little pigs
14. 02. 2008
0 views

the three little pigs

Exon HKSB
30. 10. 2007
0 views

Exon HKSB

June06SPCCUpdateJVan voorhis
07. 11. 2007
0 views

June06SPCCUpdateJVan voorhis

cultural impact hispanics tn
24. 02. 2008
0 views

cultural impact hispanics tn

SE 05 Punctuation I
29. 02. 2008
0 views

SE 05 Punctuation I

GaryCorbett e
04. 03. 2008
0 views

GaryCorbett e

Radiation Hazards
06. 03. 2008
0 views

Radiation Hazards

Portoroz
04. 10. 2007
0 views

Portoroz

jdean c10
25. 03. 2008
0 views

jdean c10

SoS
25. 03. 2008
0 views

SoS

MVestergaard SantaFe06
29. 11. 2007
0 views

MVestergaard SantaFe06

PowerPointTour
02. 11. 2007
0 views

PowerPointTour

tal daly
10. 04. 2008
0 views

tal daly

matz011
16. 04. 2008
0 views

matz011

installaware faq
17. 04. 2008
0 views

installaware faq

ATMSELong
18. 04. 2008
0 views

ATMSELong

36329938
22. 04. 2008
0 views

36329938

ITCan
10. 03. 2008
0 views

ITCan

kejian4
11. 10. 2007
0 views

kejian4

061213 dialog north korea petrov
11. 10. 2007
0 views

061213 dialog north korea petrov

Session6 Adm Wilcocks
07. 11. 2007
0 views

Session6 Adm Wilcocks

high technology surgery
30. 04. 2008
0 views

high technology surgery

Robot Convoy final presentation
07. 01. 2008
0 views

Robot Convoy final presentation

harry truman
18. 06. 2007
0 views

harry truman

goldrush
18. 06. 2007
0 views

goldrush

GMK
18. 06. 2007
0 views

GMK

gatech
18. 06. 2007
0 views

gatech

fusion be
18. 06. 2007
0 views

fusion be

Fun Facts updated 3 05
18. 06. 2007
0 views

Fun Facts updated 3 05

Geomatic AAU 07032007 forkortet
18. 06. 2007
0 views

Geomatic AAU 07032007 forkortet

General Spring Intro
18. 06. 2007
0 views

General Spring Intro

intervento Ambrosi Legge125
18. 06. 2007
0 views

intervento Ambrosi Legge125

insostegno
18. 06. 2007
0 views

insostegno

Inhalts angabe
18. 06. 2007
0 views

Inhalts angabe

Implant Simulations
18. 06. 2007
0 views

Implant Simulations

implantate berlin
18. 06. 2007
0 views

implantate berlin

Imber stud
18. 06. 2007
0 views

Imber stud

hsm bend2
18. 06. 2007
0 views

hsm bend2

history mat storia dei diritti
18. 06. 2007
0 views

history mat storia dei diritti

headquarters structure
18. 06. 2007
0 views

headquarters structure

Department Of Conservation
23. 10. 2007
0 views

Department Of Conservation

Hippo
18. 07. 2008
0 views

Hippo

pa3 disare ppt
28. 09. 2007
0 views

pa3 disare ppt

Sudan Polio Update 03 05
21. 10. 2007
0 views

Sudan Polio Update 03 05

bradford ancer
21. 08. 2007
0 views

bradford ancer

Delaunay Triangulations
15. 06. 2007
0 views

Delaunay Triangulations

Bayesian analysis and problems
15. 06. 2007
0 views

Bayesian analysis and problems

Biofuels - Think Big
15. 06. 2007
0 views

Biofuels - Think Big

AVO  - Virtual Observatory
15. 06. 2007
0 views

AVO - Virtual Observatory

PHOBOS Collaboration
15. 06. 2007
0 views

PHOBOS Collaboration

gennaipm
18. 06. 2007
0 views

gennaipm

sigcse2003
07. 12. 2007
0 views

sigcse2003

Introductionto Kyrgyzstan
26. 11. 2007
0 views

Introductionto Kyrgyzstan

HIT SAN
18. 06. 2007
0 views

HIT SAN

Metzenbaum Shelley
23. 10. 2007
0 views

Metzenbaum Shelley

ppt CHAP018
24. 02. 2008
0 views

ppt CHAP018

lesson3 warm up
07. 04. 2008
0 views

lesson3 warm up

shelving with lcc
19. 02. 2008
0 views

shelving with lcc

25ConnectionsV5 p2
18. 10. 2007
0 views

25ConnectionsV5 p2

2506043
15. 11. 2007
0 views

2506043

TravelChapter7 3
27. 03. 2008
0 views

TravelChapter7 3

french rfp
18. 06. 2007
0 views

french rfp

BEFxii Coronado
09. 04. 2008
0 views

BEFxii Coronado

spectrumastrotalk
28. 11. 2007
0 views

spectrumastrotalk

metadata frames
05. 10. 2007
0 views

metadata frames

Dancefinal
27. 11. 2007
0 views

Dancefinal